Schizophrenia Research
Volume 73, Issue 2 , Pages 357-366 , 1 March 2005

Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics

  • Niels Bergemann

      Affiliations

    • Department of Psychiatry, University of Heidelberg, Voss-Str. 4, D-69115 Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6221 56 5411; fax: +49 6221 56 5477.
    • ,
  • Christoph Mundt

      Affiliations

    • Department of Psychiatry, University of Heidelberg, Voss-Str. 4, D-69115 Heidelberg, Germany
    • ,
  • Peter Parzer

      Affiliations

    • Department of Child and Adolescent Psychiatry, University of Heidelberg, Germany
    • ,
  • Iris Jannakos

      Affiliations

    • Department of Psychiatry, University of Heidelberg, Voss-Str. 4, D-69115 Heidelberg, Germany
    • ,
  • Ines Nagl

      Affiliations

    • Department of Psychiatry, University of Heidelberg, Voss-Str. 4, D-69115 Heidelberg, Germany
    • ,
  • Birgit Salbach

      Affiliations

    • Department of Obstetrics and Gynecology, University of Heidelberg, Germany
    • ,
  • Klaus Klinga

      Affiliations

    • Department of Obstetrics and Gynecology, University of Heidelberg, Germany
    • ,
  • Benno Runnebaum

      Affiliations

    • Department of Obstetrics and Gynecology, University of Heidelberg, Germany
    • ,
  • Franz Resch

      Affiliations

    • Department of Child and Adolescent Psychiatry, University of Heidelberg, Germany

Received 12 June 2004 ,Accepted 21 June 2004.

References 

  1. Albus M, Maier W. Lack of gender differences in age at onset in familial schizophrenia. Schizophr. Res. 1995;18:51–57
  2. Angermeyer MC, Buser K, Patzold U, Piccolo P. Gender differences in age at onset of schizophrenia. An review. Eur. Arch. Psychiatr. Neurol. Sci. 1988;237:351–364
  3. Behl C. Estrogens—Mystery Drug for the Brain. The Neuroprotective Activities of the Female Sex Hormone. Wien: Springer; 2001;
  4. In:  Bergemann N,  Riecher-Rössler A editor. Estrogens Effects in Psychiatric Disorders. Wien: Springer; 2004;
  5. Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt Ch, et al. Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Archives of Women's Mental Health. 2002;5:119–126
  6. Bergemann, N., Mundt, Ch., Parzer, P., Pakrasi, M., Eckstein-Mannsperger, U., Haisch, S., Salbach, B., Klinga, K., Runnebaum, B., Resch, F., 2004a. No additional effect of estrogen as an adjuvant therapy to antipsychotics for relapse prevention on the psychopathology and the course of illness in women with schizophrenia: results of a placebo-controlled double-blind study. Submitted for publication.
  7. Bergemann N, Mundt Ch, Parzer P, Runnebaum B, Resch F. Hypoestrogenmism and estrogen replacement therapy in women suffering from schizophrenia. In:  Bergemann N,  Riecher-Rössler A editor. Estrogen Effects in Psychiatric Disorders. Wien, New York: Springer; 2004;p. 123–144
  8. Bleuler E. Die spätschizophrenen Krankheitsbilder. Neurologie. 1943;15:259–290
  9. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111:11–20
  10. Chang SS, Renshaw DC. Psychosis and pregnancy. Compr. Ther. 1986;12:36–41
  11. Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom. Med. 2001;63:822–829
  12. Cohen RZ, Seeman MV, Gotowiec A, Kopala L. Earlier puberty as a predictor of later onset of schizophrenia in women. Am. J. Psychiatry. 1999;156:1059–1064
  13. DeLisi LE, Dauphinais ID, Hauser P. Gender differences in the brain: are they relevant to pathogenesis of schizophrenia?. Compr. Ther. 1989;30:197–208
  14. Diczfalusy E, Lauritzen C. Östrogene beim Menschen. Berlin: Springer; 1961;
  15. DiPaolo T. Modulation of brain dopamine transmission by sex steroids. Review of the Neurosciences. 1994;5:27–42
  16. Fink G, Sumner BEH, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell. Mol. Neurobiol. 1996;16:325–344
  17. Fink G, Sumner BEH, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol. 1998;25:764–775
  18. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog. Neurobiol. 2001;63:29–60
  19. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol. Psychiatry. 1994;36:137–139
  20. Gordon JH, Borison RL, Diamond BI. Modulation of dopamine receptor sensitivity by estrogen. Biol. Psychiatry. 1980;15:389–396
  21. Häffner R. Beziehungen zwischen Menstruation und Nerven-und Geisteskrankheiten auf Grund der Literatur und klinischer Studien. Z. Gesamte Neurol. Psychiatr. 1912;9:154–223
  22. Häfner H, Behrens S, De Vry J, Gattaz F. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur. Arch. Psychiatry Clin. Neurosci. 1991;241:65–68
  23. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W. First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences. Eur. Arch. Psychiatry Clin. Neurosci. 1992;242:109–118
  24. Häfner H, an der Heiden W, Behrens S, Gattaz F, Hambrecht M, Löffler W, et al. Causes and consequences of the gender differences in age at onset of schizophrenia. Schizophr. Bull. 1998;24:99–113
  25. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in postmenopausal women. Biol. Psychiatry. 1995;37:434–441
  26. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am. J. Psychiatry. 2001;158:1134–1139
  27. Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology. 2001;26:27–35
  28. Jolly Ph. Menstruation und psychose. Arch. Psychiatr. Nervenkr. 1915;55:637–686
  29. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br. J. Psychiatry. 1987;150:662–673
  30. Klinga K. Determination of hormones and hormone receptors. In:  Runnebaum B,  Rabe T editor. Gynecological Endocrinology and Reproductive Medicine. vol. 1:Heidelberg: Springer; 1994;p. 45–54
  31. Könnecke R, Häfner H, Maurer K, Löffler W, an der Heiden W. Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of oestrogen in women. Schizophr. Res. 2000;44:81–93
  32. Kraepelin E. Psychiatrie. Band. 1–4. Leipzig: Barth; 1909;
  33. Krafft-Ebing RV. Untersuchungen über das Irresein zur Zeit der Menstruation. Arch. Psychiatr. Nervenkr. 1878;8:65–107
  34. Kulkarni J. Clinical estrogen trials in patients with schizophrenia. In:  Bergemann N,  Riecher-Rössler A editor. Estrogens Effects in Psychiatric Disorders. Wien: Springer; 2004;
  35. Kulkarni J, deCastella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 1996;20:247–252
  36. Kulkarni J, deCastella A, Riedel A, Taffe J, Fitzgerald P, Burger H. Estrogen—a potential new treatment in schizophrenia. Schizophr. Res. 2001;48:137–144
  37. Lee SJ, McEwen BS. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2001;41:569–591
  38. Leidenberger FA. Klinische Endokrinologie für Frauenärzte. Berlin: Springer; 1992;
  39. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?. Biol. Psychiatry. 2001;49:47–51
  40. Mahé V, Dumaine A. Oestrogen withdrawal associated psychoses. Acta Psychiatr. Scand. 2001;104:323–331
  41. Mayer CEL. Menstruation im Zusammenhange mit psychischen Störungen. Beitr. Geburtshilfe Gynaekol. 1872;1:111–135
  42. McEwen BS, Alvers SE. Estrogen actions in the central nervous system. Endocr. Rev. 1999;20:279–307
  43. Melkersson KI, Hulting A-L, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br. J. Clin. Pharmacol. 2001;51:317–324
  44. Morissette M, DiPaolo T. Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology. 1993;58:16–22
  45. Notman MT, Nadelson CC. The hormone replacement therapy controversy. Archives of Women's Mental Health. 2002;5:33–35
  46. Rabe T, Runnebaum B. Hormones. In:  Runnebaum B,  Rabe T editor. Gynecological Endocrinology and Reproductive Medicine. vol. 1:Heidelberg: Springer; 1997;p. 1–43
  47. In:  Reiss M editors. Psychoendocrinology. Orlando: Grune & Stratton; 1958;
  48. Riecher-Rössler A. Oestrogens and schizophrenia. Curr. Opin. Psychiatry. 2003;16:187–192
  49. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994;20:203–214
  50. Ross SM. Menstruation in its relationships to insanity. J. Ment. Sci. 1909;55:270–280
  51. Schaefer A. Einfluss der Psychose auf den Menstruationsvorgang. Allgem. Zeitschr. f. Psych. 1894;50:976–996
  52. Schroeter, R., 1874. Die Menstruation in ihren Beziehungen zu den Psychosen. Zeitschrift für Psychiatrie, part 1: 30, 551–572, part 2: 31 234–250.
  53. Seeman MV. Psychopathology in women and men: focus on female hormones. Am. J. Psychiatry. 1997;154:1641–1647
  54. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic induced hyperprolactinaemia on the hypothalamic–pituitary–gonadal axis. J. Clin. Psychopharmacol. 2002;22:109–114
  55. Stata Corp. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation; 2003;
  56. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause. 2003;10:497–506
  57. The Writing Group of the International Menopause Society Executive Committee. Guidelines for the hormone treatment of women in the menopause transition and beyond. Position statement by the Executive Committee of the International Menopause Society. Climacteric. 2004;7:8–11
  58. Turgeon JL, McDonnel DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304:1269–1273
  59. Warner MD, Walker AM, D'Souza DC, Lee D, Nasseri D, Peabody CA. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Res. 2001;102:249–254
  60. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333

PII: S0920-9964(04)00210-5

doi: 10.1016/j.schres.2004.06.013

Schizophrenia Research
Volume 73, Issue 2 , Pages 357-366 , 1 March 2005

Article Tools

* Image Usage & Resolution